Drug Trial Radar · NCT06411301
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 2024
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Jules Bordet InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- RayzeBio, Inc.
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine the safety and the recommended phase II dose of RYZ101 (actinium-225 labelled DOTA-octreotate (225Ac-DOTATATE)) in participants with refractory and relapsing multiple myeloma (MM) that have received at least 3 prior lines of myeloma therapy. Participants will be selected based on somatostatin receptor (SSTR) positivity assessed by gallium-68 labelled DOTA-octreotate (68Ga-DOTATATE) PET/CT. The response to 225Ac-DOTATATE therapy will also be assessed in the target study population.
Conditions
- Multiple Myeloma, Refractory
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
Interventions
225Ac-DOTATATEDrug
Two intravenous infusions every 6 weeks (Q6W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of 225Ac-DOTATATETime frame: First 84 days following first 225Ac-DOTATATE injection
- Recommended phase II dose of 225Ac-DOTATATETime frame: First 84 days following first 225Ac-DOTATATE injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jules Bordet Institute
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.